P3 Health Partners Inc. (NASDAQ:PIII) Sees Large Growth in Short Interest

P3 Health Partners Inc. (NASDAQ:PIII) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 27,237 shares, an increase of 72.0% from the January 15th total of 15,836 shares. Based on an average daily volume of 29,534 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.5% of the company’s shares are short sold. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 29,534 shares, the days-to-cover ratio is currently 0.9 days.

Hedge Funds Weigh In On P3 Health Partners

A hedge fund recently raised its stake in P3 Health Partners stock. Trinity Financial Advisors LLC lifted its stake in shares of P3 Health Partners Inc. (NASDAQ:PIII) by 4.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 26,678 shares of the company’s stock after buying an additional 1,178 shares during the quarter. Trinity Financial Advisors LLC owned about 0.37% of P3 Health Partners worth $239,000 as of its most recent filing with the Securities & Exchange Commission. 7.75% of the stock is currently owned by institutional investors and hedge funds.

P3 Health Partners Stock Performance

Shares of PIII opened at $2.14 on Friday. The company has a current ratio of 0.32, a quick ratio of 0.32 and a debt-to-equity ratio of 2.29. The firm’s fifty day simple moving average is $3.25 and its two-hundred day simple moving average is $6.21. P3 Health Partners has a 12 month low of $1.52 and a 12 month high of $12.36. The stock has a market capitalization of $15.43 million, a P/E ratio of -0.05 and a beta of 0.89.

P3 Health Partners (NASDAQ:PIII) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($9.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.70) by ($0.97). P3 Health Partners had a negative net margin of 9.07% and a negative return on equity of 302.33%. The business had revenue of $345.25 million during the quarter, compared to analyst estimates of $346.64 million. As a group, analysts predict that P3 Health Partners will post -0.67 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of P3 Health Partners in a report on Thursday, January 22nd. Lake Street Capital lowered their price objective on P3 Health Partners from $20.00 to $12.50 and set a “buy” rating for the company in a research report on Monday, November 17th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of P3 Health Partners in a research note on Friday, December 12th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.50.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.